JPWO2020204161A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020204161A5
JPWO2020204161A5 JP2021512320A JP2021512320A JPWO2020204161A5 JP WO2020204161 A5 JPWO2020204161 A5 JP WO2020204161A5 JP 2021512320 A JP2021512320 A JP 2021512320A JP 2021512320 A JP2021512320 A JP 2021512320A JP WO2020204161 A5 JPWO2020204161 A5 JP WO2020204161A5
Authority
JP
Japan
Prior art keywords
composition
hydroxy
extracellular vesicles
alkyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512320A
Other languages
English (en)
Japanese (ja)
Other versions
JP7508048B2 (ja
JPWO2020204161A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/015310 external-priority patent/WO2020204161A1/ja
Publication of JPWO2020204161A1 publication Critical patent/JPWO2020204161A1/ja
Publication of JPWO2020204161A5 publication Critical patent/JPWO2020204161A5/ja
Application granted granted Critical
Publication of JP7508048B2 publication Critical patent/JP7508048B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512320A 2019-04-04 2020-04-03 細胞外小胞の分泌を促進するための組成物 Active JP7508048B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019071759 2019-04-04
JP2019071759 2019-04-04
PCT/JP2020/015310 WO2020204161A1 (ja) 2019-04-04 2020-04-03 細胞外小胞の分泌を促進するための組成物

Publications (3)

Publication Number Publication Date
JPWO2020204161A1 JPWO2020204161A1 (https=) 2020-10-08
JPWO2020204161A5 true JPWO2020204161A5 (https=) 2023-03-17
JP7508048B2 JP7508048B2 (ja) 2024-07-01

Family

ID=72669110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512320A Active JP7508048B2 (ja) 2019-04-04 2020-04-03 細胞外小胞の分泌を促進するための組成物

Country Status (4)

Country Link
US (1) US20220162561A1 (https=)
EP (1) EP3950060A4 (https=)
JP (1) JP7508048B2 (https=)
WO (1) WO2020204161A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102159915B1 (ko) * 2019-09-18 2020-09-24 주식회사 엑소코바이오 엑소좀 및/또는 세포외 소포체의 생성 촉진 방법
WO2022080461A1 (ja) * 2020-10-16 2022-04-21 富士フイルム和光純薬株式会社 細胞外小胞の産生用培地、培地キット、添加剤及び細胞外小胞の産生方法
CN112592892B (zh) * 2020-12-25 2022-04-22 新疆赛尔托马斯生物科技有限公司 一种诱导脐带间充质干细胞因子分泌的培养基及培养方法
US20250270564A1 (en) * 2021-10-11 2025-08-28 Theoria Science Inc. Extracellular vesicle secretion booster for boosting extracellular vesicle secretion, and use thereof
US11622949B1 (en) 2022-08-04 2023-04-11 Gad M. Gilad Agmatine compositions for treatment of osteoarthritis
JP7371975B1 (ja) 2022-09-27 2023-10-31 セルソース株式会社 細胞外小胞の製造方法及び細胞外小胞含有組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002047673A2 (en) * 2000-12-15 2002-06-20 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
AU2008311827A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
US20100189683A1 (en) * 2008-11-14 2010-07-29 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
KR101662405B1 (ko) 2013-12-12 2016-10-05 사회복지법인 삼성생명공익재단 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물
EP3102191A1 (en) 2014-02-05 2016-12-14 Stc.Unm Exosomes as a therapeutic for cancer
US9750761B2 (en) * 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
WO2016167373A1 (ja) 2015-04-16 2016-10-20 日産化学工業株式会社 培地添加物及び培地組成物並びにそれらを用いた細胞又は組織の培養方法
EP3333254B1 (en) 2015-08-03 2025-05-14 Osaka University Mesenchymal stem cell-derived exosome
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
US20180133212A1 (en) * 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
EP4035659A1 (en) * 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
JP6981619B2 (ja) 2017-03-14 2021-12-15 株式会社ダイセル エクソソーム産生促進剤
CN110475856B (zh) 2017-03-30 2024-05-24 日产化学株式会社 使用纳米纤维的细胞培养
US20200171092A1 (en) 2017-06-09 2020-06-04 Osaka University Therapeutic agent for dilated cardiomyopathy

Similar Documents

Publication Publication Date Title
JPWO2020204161A5 (https=)
ES2646834T3 (es) Inhibidores de autotaxina y usos de los mismos
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
JP6517197B2 (ja) 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
US20250134868A1 (en) Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
JP2010510976A5 (https=)
DK1673398T3 (da) Multispecifikke, deimmuniserede CD3-bindere
JP2010138190A5 (https=)
RU2012110882A (ru) Производные 6-аминохиназолина или 3-цианохинолина, способы их получения и их фармацевтические применения
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
RU2012155118A (ru) Способы лечения биполярного расстройства
JP2013538802A5 (https=)
JP2011524422A5 (https=)
JP2011519910A5 (https=)
JP2013536188A5 (https=)
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
JP2010520243A5 (https=)
AR051754A1 (es) Metodos para preparar compuestos de indazol
TWI774829B (zh) 具有纖維化抑制作用之細胞層片
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
CN103409365A (zh) 一种短须裂腹鱼心脏细胞系的构建和超低温冷冻保存方法
RU2016112053A (ru) Композиции для лечения гипертензии и/или фиброза
RU2018115278A (ru) Egfr киназы ингибитор, способ его получения и применения
MX2008003187A (es) Un procedimiento mejorado para preparar compuestos de aminodiol protegidos con oxazodilina, utiles como intermediarios para el florfenicol.
PE20030661A1 (es) N-[4-(1H-IMIDAZOL-1IL)-2-FLUOROFENIL]-3-(TRIFLUOROMETIL)-1H-PIRAZOL-5-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa